The department’s updated guidelines will exempt physicians from certain certification requirements necessary to prescribe the drug for opioid use disorder treatment.
Before the updated guidelines, physicians seeking to prescribe buprenorphine outside of opioid treatment programs were required to complete an eight-hour course, often waiting 60 to 90 days to receive their waiver once the course was completed.
“Removing some of the certification requirements for an X-waiver for physicians is a step toward providing more people struggling with this chronic disease access to medication assisted treatment,” HHS Assistant Secretary for Health Brett Giroir, MD, said in a news release.
Physicians who utilize the exemption must only treat patients located in the states in which they are licensed and may treat no more than 30 patients with buprenorphine for opioid use disorder at any one time.
The American College of Emergency Physicians issued a statement Jan. 14 supporting the measure in which its president, Mark Rosenberg, DO, called the X-waiver ” an outdated and cumbersome barrier to treatment.”
More articles on opioids:
Walmart pharmacists warned for years about potentially illegal opioid sales, report finds
How Delaware is using the money from its opioid impact charge
License revoked for Florida physician accused of inappropriately prescribing opioids, asking patient for $35K
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
